Neurocrine Biosciences Reports Third Quarter 2021 Financial Results

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the third quarter ended September 30, 2021. "Our third...

Related Keywords

Japan ,United States ,Neurocrine Biosciences ,Neurocrine Bioscience ,Kevin Gorman ,Neurocrine Biosciences Inc ,Linkedin ,European Union ,Takeda Pharmaceutical Company Limited ,Ministry Of Health ,Mitsubishi Tanabe Pharma Corporation Submitted Marketing Authorization ,Nasdaq ,Chief Executive Officer ,Product Sales ,Commercial Highlights ,In Process Research ,Key Activities ,Top Line Data Expected ,Cerebral Palsy ,Neurological Indication ,Registrational Study ,Psychiatric Indication ,Adrenal Hyperplasia ,Impairment Associated ,Major Depressive Disorder ,Pediatric Epilepsy ,Epileptic Encephalopathy ,Continuous Spike ,Wave During Sleep ,Onset Seizure ,Developmental Epileptic Encephalopathy ,Webcast Today ,Nc ,